We and others recently showed that the orphan nuclear receptor RORα is downregulated in cancer tissues and cell lines and that expression of RORα results in tumor suppressive activities [5–7], suggesting that RORα is a potential drug target for breast cancer treatment. This evidence concerns the gene RORA and breast carcinoma.